Selecting Drug Delivery Systems For Higher Doses, Higher Viscosities, And Lower Risk
By Nicolas Bralet and Megan Lan, MBA, MA

The development of new parenteral biologics with high-volume, high-viscosity formulations (> 1 mL, >15 cP) is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection.1-3 As these formulations come to market, pharmaceutical and biotech companies must make critical device choices from an array of largely unproven options.2 The following article discusses how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
BD Medical - Pharmaceutical Systems
This website uses cookies to ensure you get the best experience on our website. Learn more